GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (FRA:PSH0) » Definitions » EV-to-EBIT

Sernova Biotherapeutics (FRA:PSH0) EV-to-EBIT : -2.20 (As of May. 10, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Sernova Biotherapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sernova Biotherapeutics's Enterprise Value is €40.57 Mil. Sernova Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Jan. 2025 was €-18.43 Mil. Therefore, Sernova Biotherapeutics's EV-to-EBIT for today is -2.20.

The historical rank and industry rank for Sernova Biotherapeutics's EV-to-EBIT or its related term are showing as below:

FRA:PSH0' s EV-to-EBIT Range Over the Past 10 Years
Min: -2.5   Med: 0   Max: 0
Current: -2.32

FRA:PSH0's EV-to-EBIT is ranked worse than
100% of 485 companies
in the Biotechnology industry
Industry Median: 5.9 vs FRA:PSH0: -2.32

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Sernova Biotherapeutics's Enterprise Value for the quarter that ended in Jan. 2025 was €44.33 Mil. Sernova Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Jan. 2025 was €-18.43 Mil. Sernova Biotherapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2025 was -41.58%.


Sernova Biotherapeutics EV-to-EBIT Historical Data

The historical data trend for Sernova Biotherapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics EV-to-EBIT Chart

Sernova Biotherapeutics Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.92 -43.28 -7.95 -5.41 -2.40

Sernova Biotherapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.33 -2.90 -2.01 -2.40 -2.62

Competitive Comparison of Sernova Biotherapeutics's EV-to-EBIT

For the Biotechnology subindustry, Sernova Biotherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sernova Biotherapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova Biotherapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sernova Biotherapeutics's EV-to-EBIT falls into.


;
;

Sernova Biotherapeutics EV-to-EBIT Calculation

Sernova Biotherapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=40.566/-18.43
=-2.20

Sernova Biotherapeutics's current Enterprise Value is €40.57 Mil.
Sernova Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-18.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sernova Biotherapeutics  (FRA:PSH0) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sernova Biotherapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jan. 2025 ) =EBIT / Enterprise Value (Q: Jan. 2025 )
=-18.43/44.3285055
=-41.58 %

Sernova Biotherapeutics's Enterprise Value for the quarter that ended in Jan. 2025 was €44.33 Mil.
Sernova Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-18.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sernova Biotherapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sernova Biotherapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sernova Biotherapeutics Business Description

Traded in Other Exchanges
Address
700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8
Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.

Sernova Biotherapeutics Headlines

No Headlines